New schedule of bevacizumab/paclitaxel as first‐line therapy for metastatic HER2‐negative breast cancer in a real‐life setting

Angiogenesis plays an essential role in the growth and progression of breast cancer. This observational single center study evaluated the efficacy and safety of a new weekly schedule of bevacizumab/paclitaxel combination in the first‐line treatment of unselected, HER2‐negative, metastatic breast can...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Cannita, Katia, Paradisi, Stefania, Cocciolone, Valentina, Bafile, Alberto, Rinaldi, Lucia, Irelli, Azzurra, Lanfiuti Baldi, Paola, Zugaro, Luigi, Manetta, Rosa, Alesse, Edoardo, Ricevuto, Enrico, Ficorella, Corrado
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5055157/
https://ncbi.nlm.nih.gov/pubmed/27416882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.803
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados